XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Termination Benefits
6 Months Ended
Jun. 30, 2024
Termination Benefits [Abstract]  
Termination Benefits Termination Benefits
2023 Reduction in Workforce
During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2024202320242023
Cost of products and services sold$— $334 $— $369 
Research and development— — — 566 
Sales and marketing— 94 — 1,542 
General and administrative— 201 — 787 
$— $629 $— $3,264 
As of June 30, 2024 the Company had fully paid the $3.3 million related to the reduction in workforce. No additional expense associated with the 2023 reduction in workforce was incurred during the six months ended June 30, 2024. This plan was completed as of June 30, 2024.
Q1 2024 Reduction in Workforce
During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):
For the Six Months Ended June 30,
2024
Cost of products and services sold$231 
Research and development87 
Sales and marketing69 
General and administrative17 
$404 
As of June 30, 2024 the Company had $51.8 thousand accrued and had paid $0.4 million related to the reduction in workforce. No additional expense associated with the Q1 2024 reduction in workforce was incurred during the three months ended June 30, 2024. The Company expects this plan to be completed by December 31, 2024.
Q2 2024 Reduction in Workforce
During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31,
2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):
For the Three Months Ended June 30,
2024
Cost of products and services sold$889 
Research and development478 
Sales and marketing125 
General and administrative160 
Total$1,652 
As of June 30, 2024 the Company had $1.5 million accrued and had paid $0.2 million related to the reduction in workforce. The Company expects this plan to be completed by September 2025.